

Test Description

MSI testing is used for Hereditary Cancer screening (Hereditary Non-Polyposis Colorectal Cancer -HNPCC or Lynch syndrome); As a biomarker (Prognostic and predictive biomarker for the response of Immunotherapy)

Clinician

Clinician Name: Dr Shelly Mahajan
 Medical Facility: Mahajan Imaging, Caring dx
 Pathologist: Not Provided

Patient Demographic

Name: Ranjan Kumar Sharma
 Sex: Male
 Date of Birth/Age: 60 years
 Disease: Adenocarcinoma

Specimen

Site: Gastric Biopsy
 Sample Type: FFPE block S-7371/19
 Date of Collection: 19-09-2019
 Date of Booking: 19-09-2019

iMSI RapidTM Assay

Result Microsatellite - Stable (MSS)

BIOMARKER FINDINGS

<i>ACVR2A</i>	No Mutation detected
<i>BTBD7</i>	No Mutation detected
<i>DIDO1</i>	No Mutation detected
<i>MRE11</i>	No Mutation detected
<i>RYR3</i>	No Mutation detected
<i>SEC13A</i>	No Mutation detected
<i>SULF2</i>	No Mutation detected

INTERPRETATION

Mutations are not detected in any of the 7 markers

*MSS <2 of the 7 markers demonstrate instability

#MSI-H ≥2 of the 7 markers demonstrate instability

*Microsatellite stable

Microsatellite Instability-High

For valid batch test results specific controls are being run with every batch.

METHODOLOGY

Multiplex detection of seven mononucleotide repeats using molecular beacon probe-based polymerase chain reaction followed by high resolution melt-curve analysis. The assay uses seven novel biomarkers *ACVR2A*, *BTBD7*, *DIDO1*, *MRE11*, *RYR3*, *SEC31A* and *SULF2* as this set of biomarkers is stable over different cancer types and ethnicities and show high performance than other known assays like *Bethesda Panel*. This test is carried out on Idylla platform using the MSI/1.0 Cartridge based kit which is CE IVD approved.

REFERENCES

Zhao et al. (2014) eLife 3: e02725, 1-26.
 De Craene B. et al. (2018) ASCO Abstract #e15639.
 Zhao et al. (2018) ASCO Abstract #e15654



20 September 2019

Dr Gulshan Yadav, MD, Consultant Pathology

Date